Compare SKY & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKY | MIRM |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | SKY | MIRM |
|---|---|---|
| Price | $86.93 | $100.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $101.00 | ★ $102.64 |
| AVG Volume (30 Days) | ★ 906.1K | 805.8K |
| Earning Date | 02-03-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.12 | N/A |
| EPS | ★ 3.74 | N/A |
| Revenue | ★ $2,636,228,000.00 | $471,794,000.00 |
| Revenue This Year | $7.67 | $55.91 |
| Revenue Next Year | $4.67 | $23.97 |
| P/E Ratio | $22.33 | ★ N/A |
| Revenue Growth | 8.67 | ★ 53.66 |
| 52 Week Low | $59.44 | $36.88 |
| 52 Week High | $110.00 | $105.74 |
| Indicator | SKY | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 64.10 |
| Support Level | $74.62 | $97.49 |
| Resistance Level | $87.70 | $105.74 |
| Average True Range (ATR) | 4.31 | 3.93 |
| MACD | -0.49 | -0.55 |
| Stochastic Oscillator | 55.14 | 66.23 |
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.